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Introduction
In 1906, Von Pirquet used the term “supersensitivity without immunity” to describe; (i) the 
symptoms of inhalant allergy, (ii) the positive immediate skin tests and (iii) the fact that 
other tests of immunity were not positive in these patients 1. The other tests he referred to 
were precipitin tests and complement fixation. Thus he opened up the question of serum 
tests for “supersensitivity”. In 1919, Ramirez reported that a patient, who had received a 
blood transfusion from a horse allergic donor, became allergic to horse dander 2. At this 
point, Prausnitz set out to investigate whether the serum of allergic subjects contained a 
factor or factors that could sensitize the skin. In 1921, he reported that the local injection of 
serum from a fish allergic subject, Kuestner, to an individual who was only allergic to 
pollen, Prausnitz, would transfer specific sensitivity 3. This transfer of sensitivity came to be 
known as the P-K test and was used widely to study sensitivity not only to common 
allergens but also to extracts as diverse as those obtained from Schistosomes 4, 5.
Furthermore, Cooke and his colleagues in New York identified that there were other 
antibodies in the serum that increased during desensitization treatment and could block the 
skin sensitizing activity 6. By the 1950’s, it was clear that the transferred sensitivity was 
specific, that it could be diluted extensively and that the skin remained locally sensitive for 
days if not weeks after the injection of serum 7, 8. It was also already clear that the ability to 
sensitize the skin was lost after moderate heating of the serum 7. Several studies had also 
been reported on the physical properties of P-K activity. Indeed Dan Campbell and his 
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colleagues at Cal Tech reported on the sedimentation properties of skin sensitizing 
antibodies in 1960 9. However, the studies prior to 1964 had not succeeded in defining the 
nature of these antibodies.
The Purification of P-K activity and evidence that it represented a new 
isotype of immunoglobulin
Around 1960, Kimishige Ishizaka set out to purify P-K activity from the serum of patients 
who were allergic to pollen. At that time, seasonal hay fever was much the most common 
form of allergic disease and these were the sera that had the highest titers of P-K activity. In 
1964, his group reported that P-K activity was present in a serum fraction that contained 
molecules larger than IgG and that included monomeric IgA 10. Those experiments actually 
suggested that P-K activity might be a property of IgA. However, he went on to disprove that 
idea based on two observations. Firstly partially purified human IgA antibodies to group A 
blood substance did not have P-K activity and secondly the P-K activity separated with 
molecules slightly larger than IgA 11. The separation of P-K activity from serum IgA was 
dependent on using two 100 cm upward flowing, gravity fed, size exclusion columns in 
series and also on the development by Pharmcia of the cross linked dextran Sephadex G200 
as a molecular sieve. This column produced a P-K rich fraction which was further depleted 
of other immunoglobulins and used to immunize rabbits. Thus by 1966, an antiserum 
specific for P-K activity had been produced that could deplete the P-K activity from serum, 
as well as give a precipitin line in a gel 12. They provided evidence at that time that this 
activity could not be ascribed to IgM, IgG, IgA or IgD antibodies and suggested that it 
should be regarded as a new isotype which they named gamma E 13, 14.
Demonstration that a myeloma derived protein ND was not IgM, IgG, IgA or 
IgD and could block sensitization of the skin
Meanwhile “back in Europe” the immunochemists Hans Bennich and Gunnar Johansson had 
become very interested in the nature of the immunoglobulin present in the serum of a patient 
(ND) who required regular plasmapheresis for multiple myeloma. From a large bank of 
myeloma sera this was the only one that could not be typed i.e. it was not IgM, IgG, IgA, or 
the newly defined IgD. The serum from this patient provided an ideal source to study since it 
contained ≥10 mg/ml of the myeloma protein. However, it is important to remember that 
myeloma proteins do not have known antigen specificity which made it difficult to 
investigate the biological activity. Nonetheless, in 1967 working with Dennis Stanworth and 
John Humphrey in the UK they digested the molecule with Papain and reported that the Fc 
fragment of the ND protein could inhibit PK activity 15–17. One of the most remarkable 
things about the whole story is that the Radio-Allergo Sorbent test (RAST) for IgE 
antibodies was also published in 1967 18. That paper by Wide, Bennich and Johansson 
reported assays of IgE to more than twenty different allergens and a significant correlation 
between the assay results and the results of challenge tests. The availability of myeloma 
protein, ND, was invaluable in the development of assays of total IgE and IgE antibodies in 
serum, because there was sufficient fully purified protein not only for the digestion with 
Papain but also for radiolabeling and production of specific anti-IgE. The protein also made 
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it possible to carry out a detailed structural analysis of the molecule which was found to 
have an extra domain in the heavy chain thereby explaining its molecular weight of close to 
190,000. In that same year, the two groups exchanged reagents and it became clear that 
Ishizaka’s purified P-K activity and the ND protein purified by Johansson and Bennich 
carried the same isotype specific determinants. By 1968, the two groups together had 
enough information to present their results to WHO 19, and the new isotype was officially 
named IgE.
Studies on the function and biology of IgE at Johns Hopkins
The importance of the discovery of IgE to our understanding of allergic disease really 
became obvious from the research that came from each of the groups over the next few 
years. In 1969, Dr. Ishizaka’s group moved from the Children’s Asthma Research Institute 
(CARI) in Denver to Johns Hopkins in Baltimore. There they pursued both the mechanisms 
of sensitization and release of histamine and also the biology of IgE antibody responses. The 
work on the role of IgE antibodies addressed the nature of the cells both in the skin and the 
circulation that bound IgE and contained histamine as well as the role of IgE in triggering 
these cells 20. Those experiments with Terruko Ishizaka and Hisaio Tomioka included, 
identifying the IgE receptor, demonstrating that the same receptor was present on basophils 
and mast cells and proving that histamine release from basophils required physical cross 
linking of two IgE receptor molecules 21.
The early evidence showing that P-K activity remained stable on the skin for many days 
implied that the receptor on the cells containing histamine must have a high affinity for IgE. 
After the discovery of IgE, this was confirmed and indeed it was suggested that the binding 
was not reversible. However, in 1973, it became clear that IgE could be stripped off 
histamine containing cells by low pH both in the mouse and in humans 22, 23. Following 
directly on the early evidence about the Fc Receptor, there have been multiple investigations 
of the mechanism of histamine release and also on the structure of the IgE receptor focused 
on explaining its high affinity. The studies on the receptor have had a checkered history with 
arguments made for a role of many different parts of the IgE molecule 23 This included 
progressively refined studies by Jean Pierre Kinet and Henry Metzger. However, the full 
crystal structure of the receptor obtained by Brian Sutton, Hannah Gould, and their 
colleagues has now allowed a convincing model of the way in which IgE binds to the 
receptor 24.
Shortly after the registration of IgE, a second patient producing high levels of IgE was 
identified in New England, who also required repeated plasmapheresis to prevent excess 
viscosity. This made it possible to develop high affinity antibodies to IgE that were used to 
study IgE on basophils and also to develop binding assays to measure IgE antibodies 25, 26. 
In Baltimore, Kishimoto and Ishizaka initiated studies to understand the mechanisms of IgE 
production using a rabbit model 27. Those studies provided good evidence that the IgE 
responses were T cell dependent. In addition, they showed that Complete Freunds Adjuvant 
(CFA) could switch off IgE production even in rabbit strains that produced excellent IgE 
responses to the same allergen using alum 28. However, it rapidly became obvious that these 
experiments would be easier in inbred strains of mice. Indeed, mice have provided an 
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excellent model for studying the cellular basis of IgE production. In many senses the full 
understanding of TH1 and TH2 came from studies involving IgE production 29, 30. Equally 
much of the understanding of the relevance of IL-4 and IL-13 came from studies on IgE 
production 31–33.
Sensitive and specific assays for IgE and IgE antibodies
After their initial work, Johansson and his colleagues focused on developing the assays for 
IgE and making them widely available 34. This included both assays for specific IgE 
antibodies and also those for the total quantity of IgE in the circulation. The techniques for 
measuring total IgE ranged from inhibition radioimmuno assay (RIA) to different forms of 
assays using anti-IgE on the solid phase. Starting with different particles or paper discs, 
these assays became progressively more accurate and technically more reliable. The assays 
for total IgE are standardized relative to an IUIS international standard, and although the 
values are generally given in international units (IU) it is widely recognized that this unit is 
equal to 2.4 ng 35, 36. Thus it became clear that a serum with 400 IU of IgE/ml contained 1 
microgram of IgE/ml which is one ten thousandth of the average quantity of IgG. Although 
the units of IgE antibodies are often given in Allergy units/ml [or kilo AU/liter] there is good 
evidence that these IgE antibody units are quantitatively the same as the IU for IgE. This 
made it possible to estimate the percentage of total IgE that was explained by specific IgE. 
The initial observations of this kind were made by Gleich and Jacob on IgE to ragweed, but 
the same is true for grass pollen and dust mite 36, 37. Most recently following IgE antibody 
responses to galactose alpha-1, 3-galactose after tick bites it is clear that this IgE response 
can be greater than 30% of the total IgE and that the specific IgE ab response can be an 
important contributor to elevated total IgE 38, 39. It is important to recognize that this is the 
only isotype of immunoglobulin in the human where specific antibodies to one antigen are 
known to make an important contribution to the total.
Since it was known that anti-IgE could cross link molecules on the surface of basophils or 
mast cells and trigger histamine release there were obvious objections to using a polyclonal 
anti-IgE to treat allergic disease. However, once the full structures of circulating IgE and 
membrane IgE were known it became clear that there were two possible sites on the 
molecule that could be targeted. The first was the FC binding site that would be shielded as 
soon as the molecule was bound to Fc epsilon R1 and the second was a small section of the 
membrane bound IgE that is close to the B cell membrane. It took over twenty years from 
the first studies on monoclonal antibodies against the Fc binding site to achieve successful 
treatment of allergic asthma with omalizumab 40, 41.
Once the assays for IgE antibodies were possible, they became a normal part of 
epidemiologic studies as well as clinical practice 42. When it became obvious that pediatric 
asthma had dramatically increased between 1960 and the 1980’s these assays played a 
central role both in defining new allergens and in investigating the role of indoor allergens in 
asthma 37, 42–45. From early on it was clear that IgE could be measured using either allergen 
extracts or purified proteins. However, it was not until the advent of recombinant proteins 
that widespread use of component assays became possible. With the dramatic rise in food 
allergy, IgE assays have played a central role both in the investigation and the management. 
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This is particularly true for conditions such as peanut allergy and delayed anaphylaxis to red 
meat where the titer of IgE antibodies to Ara h 2 and Alpha-gal, respectively, has a direct 
relationship to the disease 39, 46–48. However in Eosinophilic esophagitis (EoE) where the 
titers of IgE ab to milk are low or very low, IgE ab to milk components may nonetheless be 
relevant to designing management 49, 50.
Conclusions
There have been several previous reviews of the discovery of IgE with strikingly different 
emphasis 14, 17, 34. Looking back we have to conclude that the joint success of two different 
research approaches was remarkably good luck for those of us who care about allergic 
disease. Just at the moment when Ishizaka’s group had developed a rabbit antibody specific 
for the human antibodies that were responsible for P-K activity, Johansson and Bennich had 
identified a myeloma protein that appeared to be a novel isotype. In addition, they 
demonstrated that the Fc fragment of that protein would inhibit P-K activity. Once the two 
groups had collaborated to establish the identity of the new isotype, each group pursued their 
own research. What followed was a truly dramatic increase in research on allergic disease, 
ranging from mechanisms of histamine release, to cellular studies on the biology of IgE 
production, and the development of sensitive and accurate assays of IgE that became 
available worldwide. Thus the discovery of IgE spawned thousands of studies on the science 
of IgE as well as on the relevance of IgE antibodies to allergic disease. There have been few 
discoveries in the last 50 years that have directly resulted in such impressive progress in both 
the science and the clinical understanding of a major group of diseases.
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